CDEK
← All drugs Report issue

ak111

mAbexperimental

Clinical trial activity

8 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
5
Phase 3
2
Phase 4
0

Earliest trial started Aug 15, 2018 (NCT03622021)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06947109Phase 1May 6, 2025Akeso Pharmaceuticals, Inc.
NCT06378697Phase 3Nov 10, 2023Akeso Pharmaceuticals, Inc.
NCT06061471Phase 2Sep 14, 2023Akeso Pharmaceuticals, Inc.
NCT06066125Phase 3Mar 31, 2023Akeso Pharmaceuticals, Inc.
NCT05467995Phase 2Jun 2, 2021Akeso Pharmaceuticals, Inc.
NCT05096364Phase 2Apr 28, 2021Akeso Pharmaceuticals, Inc.
NCT05504317Phase 1May 19, 2020Akeso Pharmaceuticals, Inc.
NCT03622021Phase 1Aug 15, 2018Akeso Pharmaceuticals, Inc.
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Akeso Pharmaceuticals, Inc.For profit8832018
1 organizations
Page 1 / 1